EFFECTIVENESS AND SAFETY OUTCOMES AFTER LONG-TERM (54 WEEKS) VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE: A PROSPECTIVE, REAL-WORLD OBSERVATIONAL STUDY INCLUDING PATIENT-REPORTED OUTCOMES (POLONEZ II)

Agata Michalak  ¹     Maria Klopocka  ²     Ariel Liebert  ²     Renata Talar-Wojnarowska  ³     Danuta Domżał-Magrowska  ³     Łukasz Konecki  ⁴     Aleksandra Filipiuk  ⁴     Michal Krogulecki  ⁴     Maria Urszula Kopertowska-Majchrzak  ⁵     Kamila Stawczyk-Eder  ⁶     Katarzyna Waszak  ⁶     Piotr Eder  ⁶     Edyta Zagórowicz  ^{7, 8}     Izabela Smola  ⁹     Krzysztof Skrobot  ¹⁰     Szymon Drygała  ^11    
1 Medical University of Lublin, Lublin, Poland
² Collegium Medicum in Bydgoszcz-Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
³ Medical University of Łódź, Łódź, Poland
⁴ Military Institute of Medicine, Warsaw, Poland
⁵ General Hospital, Międzychód, Poland
⁶ Poznan University of Medical Sciences-H. Święcicki University Hospital, Poznań, Poland
⁷ The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
⁸ The Medical Center of Postgraduate Education, Warsaw, Poland
⁹ Wroclaw Medical University, Wrocław, Poland
¹⁰ Medical University of Gdansk, Gdansk, Poland
¹¹ Takeda Pharma Sp. z o.o., Warsaw, Poland

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)